“Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III RenalCell Carcinoma”, jkcvhl, vol. 13, no. 2, pp. 21–28, Jun. 2026, doi: 10.15586/jkcvhl.v13i2.455.